Results 1 to 10 of about 6,753 (182)

Cabergoline, dopamine D2 receptor agonist, prevents neuronal cell death under oxidative stress via reducing excitotoxicity. [PDF]

PLoS ONE, 2014
Several lines of evidence demonstrate that oxidative stress is involved in the pathogenesis of neurodegenerative diseases, including Parkinson's disease. Potent antioxidants may therefore be effective in the treatment of such diseases.
Haruki Odaka, Tadahiro Numakawa, Naoki Adachi, Yoshiko Ooshima, Shingo Nakajima, Yusuke Katanuma, Takafumi Inoue, Hiroshi Kunugi   +7 more
doaj   +3 more sources

Long-Term Results of Cabergoline Add-on Long-Acting Somatostatin Analogue Therapy in Acromegaly Patients [PDF]

Gazi Medical Journal
Objective: To investigate the efficacy of the dopamine agonist cabergoline in uncontrolled acromegaly despite long-acting somatostatin analog (SSA). Methods: Thirty-five patients with acromegaly who were followed up in the department of endocrinology ...
Mehmet Muhittin Yalçın, Gizem Bedir Keser, Meriç Coşkun, Afruz Babayeva, Emrah Çeltikçi, Mehmet Arda İnan, Emetullah Cindil, Aylar Poyraz, Ethem Turgay Cerit, Alev Eroğlu Altınova, Müjde Aktürk, Füsun Baloş Törüner, Mehmet Ayhan Karakoç, İlhan Yetkin   +13 more
doaj   +2 more sources

Successful Management of a Giant Pituitary Lactosomatotroph Adenoma Only with Cabergoline [PDF]

Case Reports in Endocrinology, 2013
Although advances in endocrinologic and neuroradiologic research allow easier recognition of pituitary adenomas, giant pituitary tumours are relatively rare.
Emre Bozkirli, Okan Bakiner, Emine Duygu Ersozlu Bozkirli, Eda Ertorer, Neslihan Bascil Tutuncu, Nilgun Guvener Demirag   +5 more
doaj   +2 more sources

Protective Role of Sarpogrelate in Combination with Bromocriptine and Cabergoline for Treatment of Diabetes in Alloxan-induced Diabetic Rats

Current Therapeutic Research, 2021
: Background: Although dopamine D2 receptor agonists, bromocriptine and cabergoline, are notable medications in the treatment of Parkinsonism, hyperprolactinemia, and hyperglycemia, there is an identified relationship between the utilization of D2-like ...
Mohammed Fouad Shalaby, MD, Hekma A. Abd El Latif, PhD, Mohamed El Yamani, PhD, May Ahmed Galal, PhD, Sherifa Kamal, PhD, Ikhlas Sindi, PhD   +5 more
doaj   +2 more sources

A scoping review to understand the indications, effectiveness, and limitations of cabergoline in radiological and biochemical remission of prolactinomas

Indian Journal of Endocrinology and Metabolism, 2021
Cabergoline has long been used in the medical management of prolactin-secreting pituitary adenomas. However, there is contradicting and inadequate evidence on the efficacy of cabergoline in achieving radiological and biochemical remission in prolactinoma.
Rakesh Mishra, Subhas K Konar, Adesh Shrivastava, Pradeep Chouksey, Sumit Raj, Amit Agrawal   +5 more
doaj   +2 more sources

The Effects of Cabergoline Compared to Dienogest in Women with Symptomatic Endometrioma

Fertility & Reproduction, 2021
Background: New vessel formation or neovascularization has been recognized as a feature of endometriosis. Treatment with cabergoline suppresses cell proliferation and vascular-endothelial-growth-factor-mediated angiogenesis, thereby promoting regression ...
Mehnaz Mustary Shume, Jesmine Banu, Shakeela Ishrat, Serajoom Munira, Muhammad Jasim Uddin, Sabiha Sultana   +5 more
doaj   +1 more source

Cabergoline

Reactions Weekly, 2006
europepmc   +3 more sources

DRD2 Agonist Cabergoline Abolished the Escape Mechanism Induced by mTOR Inhibitor Everolimus in Tumoral Pituitary Cells

Frontiers in Endocrinology, 2022
The mammalian target of rapamycin (mTOR) inhibitor everolimus has been shown to display antiproliferative effects on a wide spectrum of tumors. In vitro studies demonstrated that everolimus inhibited pituitary neuroendocrine tumor (PitNET) cell growth in
Federica Mangili, Emanuela Esposito, Donatella Treppiedi, Rosa Catalano, Giusy Marra, Genesio Di Muro, Anna Maria Barbieri, Marco Locatelli, Marco Locatelli, Andrea G. Lania, Andrea G. Lania, Alessandra Mangone, Alessandra Mangone, Anna Spada, Maura Arosio, Maura Arosio, Erika Peverelli, Giovanna Mantovani, Giovanna Mantovani   +18 more
doaj   +1 more source

Cardiac valvular abnormalities associated with use and cumulative exposure of cabergoline for hyperprolactinemia: the CATCH study

BMC Endocrine Disorders, 2020
Background Whether lower dose cabergoline therapy for hyperprolactinemia increases risk of valvular dysfunction remains controversial. We examined valvular abnormalities among asymptomatic adults with hyperprolactinemia treated with dopamine agonists ...
Amer Budayr, Thida C. Tan, Joan C. Lo, Jonathan G. Zaroff, Grace H. Tabada, Jingrong Yang, Alan S. Go   +6 more
doaj   +1 more source

Electrocatalytic determination of levodopa in presence of cabergoline using carbon paste electrode modified with graphene quantum dots/2-chlorobenzoyl ferrocene/ionic liquid

Journal of Electrochemical Science and Engineering, 2021
The electrochemical sensor was fabricated for the simultaneous determination of levodopa and cabergoline using carbon paste electrode (CPE) modified with graphene quantum dots (GQD), 2-chlorobenzoyl ferrocene (2CBF) and ionic liquid (IL).
Peyman Mohammadzadeh Jahani
doaj   +1 more source